PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Rhabdomyosarcomas are a malignancy of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. They account for more than half of all tissue sarcomas (ie cancer of the connective tissue) in children. Other types of sarcomas are liposarcomas, fibrosarcomas and mesenchymomas. Rhabdomyosarcomas can occur anywhere in the body but occur more commonly near muscular structures - eg, around the intestines, around the ocular muscles and in the cardiac muscle in tuberous sclerosis. The most common locations of rhabdomyosarcomas are:
- Head and neck (35-40%).
- Bladder (20%).
- Muscles, limbs, chest and abdominal wall (15-20%).
- Other sites - eg, testes.
Rhabdomyosarcomas are highly malignant and grow rapidly. They are, however, potentially curable now.
- Rhabdomyosarcomas account for 7-8% of all childhood malignant solid cancers with fewer than 60 children diagnosed per year in the UK (mostly under 10 years of age). It is actually the most common soft tissue sarcoma in children. It has a slightly higher preponderance in males than in females.
- Rhabdomyosarcomas can occur at any age but approximately 87% of patients are younger than 15 years. Rhabdomyosarcoma rarely affects adults.
- Add notes to any clinical page and create a reflective diary
- Automatically track and log every page you have viewed
- Print and export a summary to use in your appraisal
Rhabdomyosarcomas arise from rhabdomyoblasts - a primitive muscle cell. There are four types:
- Embryonal rhabdomyosarcoma - the cells have a similar appearance to embryo cells aged 6-8 weeks. This is the most common type and has a predilection for the head, neck and the genitourinary tract.
- Alveolar rhabdomyosarcoma - the cells have a similar appearance to embryo cells aged 10-12 weeks. This tends to affect older children and teenagers and has a more aggressive nature. It is associated with muscles of the trunk and limbs.
- Botryoid type - this is a variant of the embryonal type and presents as grape-like lesions in the vagina and bladder.
- Pleomorphic rhabdomyosarcoma - this entity is more common in adults and has a tendency to affect muscles of the extremities.
- Most cases are sporadic in nature.
- There is an increased risk in patients with certain genetic disorders - eg, Li-Fraumeni syndrome, neurofibromatosis, fetal alcohol syndrome and nevoid basal cell carcinoma.
- Environmental factors which may increase the risk of rhabdomyosarcoma include:
Rhabdomyosarcomas usually present as an expanding lump or swelling, which may cause pain. Other features depend upon the area of the body affected. Examples include:
- Nose - nasal obstruction and discharge.
- Eyes - protrusion of the eyeball.
- Abdomen - pain and change in bowel habit.
- Bladder - haematuria.
Non-resolving lumps in children should be investigated by a centre recognised by the United Kingdom Children's Cancer Study Group, as they will have better expertise in these rare tumours.
- Blood tests: FBC may show anaemia; LFTs may show a raised ALT and raised LDH. Urinalysis may show haematuria associated with renal tract involvement. Renal function tests and electrolytes should also be checked.
- Bone marrow studies may be required (to look for infiltration).
- Radiological imaging - this may include CXR and ultrasonography, and may proceed to CT or MRI scanning. More recently, positron emission tomography (PET) using radioisotope fluorodeoxyglucose (18F) (FDG-PET) scanning looks promising, especially in staging of the neoplasia.
- Bone scan to look for metastases.
- Biopsy for diagnosis and molecular studies.
- MyoD1 is an immature protein found in developing skeletal muscle, which disappears once the muscle matures and can be used as an immunohistochemical marker.
Initially, staging was identified by the Intergroup Rhabdomyosarcoma Study Group (IRSG) into the following groups:
- I: localised disease that is completely resected.
- IIA: resected tumour with microscopic residual disease.
- IIB: completely resected disease with involvement of lymph nodes.
- IIC: resected tumour with microscopic residual disease (at primary site) and involvement of lymph nodes. There may also be histological involvement of the most distal regional node.
- III: incomplete resection with lots of residual disease or biopsy alone of the primary site. The majority of patients belong to this group.
- IV: distant metastases at the time of diagnosis.
However, the IRSG combined with another group to form the Children's Oncology Group and the above stages have been combined with the tumour, nodes, metastases (TNM) staging system to provide new stages, as follows:
- Disease only in favourable sites, ie the orbit, head and neck (but not parameningeal), genitourinary region (but not bladder or prostate), or biliary tract.
- Disease of any other primary site (unfavorable sites). Tumours must be ≤5 cm, and no lymph node involvement.
- Disease of any other primary site but >5 cm and/or lymph node involvement.
- Metastatic disease at diagnosis.
This is recommended for all lesions, provided it is feasible, and as much of the tumour should be removed as possible. Surgery is only occasionally possible, as the tumour is usually deeply embedded in surrounding tissue. If the rhabdomyosarcoma is in an extremity then amputation is required. Surgery may also be the only way to obtain a tissue biopsy.
This is given postoperatively and pre-operatively to shrink tumour size. Vincristine, dactinomycin (actinomycin D) and cyclophosphamide (VAC) have been considered the gold standard. Dose intensification has been used to try to improve outcomes in children with rhabdomyosarcomas. However, one trial looking at dose intensification of cyclophosphamide failed to find an improved outcome. There have also been good results with the use of etoposide and ifosfamide.
This is given postoperatively and occasionally pre-operatively to shrink tumour size and commonly in head, neck and pelvic tumours.
- The five-year overall survival rate is 72% with two thirds of children being cured.
- In patients with localised disease, overall five-year survival rates have improved to more than 80% with the combined use of surgery, radiotherapy and chemotherapy.
- However, there has been little progress in managing metastatic disease with a five-year event-free survival rate of less than 30%.
- The embryonal type is the most treatable and has the most favourable prognosis.
- Location of the tumour also affects the prognosis, with orbital and genitourinary tract rhabdomyosarcomas having the most favourable prognosis.
Further reading & references
- Paulino AC, Okcu MF; Rhabdomyosarcoma. Curr Probl Cancer. 2008 Jan-Feb;32(1):7-34.
- McDowell HP; Update on childhood rhabdomyosarcoma. Arch Dis Child. 2003 Apr;88(4):354-7.
- Hayes-Jordan A, Andrassy R; Rhabdomyosarcoma in children. Curr Opin Pediatr. 2009 Jun;21(3):373-8. doi: 10.1097/MOP.0b013e32832b4171.
- Ruiz-Mesa C, Goldberg JM, Coronado Munoz AJ, et al; Rhabdomyosarcoma in adults: new perspectives on therapy. Curr Treat Options Oncol. 2015 Jun;16(6):27. doi: 10.1007/s11864-015-0342-8.
- Grufferman S, Ruymann F, Ognjanovic S, et al; Prenatal X-ray exposure and rhabdomyosarcoma in children: a report from the children's oncology group. Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1271-6. doi: 10.1158/1055-9965.EPI-08-0775. Epub 2009 Mar 17.
- Shrestha A, Ritz B, Ognjanovic S, et al; Early life factors and risk of childhood rhabdomyosarcoma. Front Public Health. 2013 May 31;1:17. doi: 10.3389/fpubh.2013.00017. eCollection 2013.
- Tateishi U, Hosono A, Makimoto A, et al; Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med. 2009 Feb;23(2):155-61. Epub 2009 Feb 19.
- Stuart A, Radhakrishnan J; Rhabdomyosarcoma. Indian J Pediatr. 2004 Apr;71(4):331-7.
- Childhood Rhabdomyosarcoma Treatment - for health professionals; National Cancer Institute
- Breitfeld PP, Meyer WH; Rhabdomyosarcoma: new windows of opportunity. Oncologist. 2005 Aug;10(7):518-27.
- Spunt SL, Smith LM, Ruymann FB, et al; Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6072-9.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
Dr Gurvinder Rull
Dr Roger Henderson
Dr Adrian Bonsall